Immunization of mice by Hollow Mesoporous Silica Nanoparticles as carriers of Porcine Circovirus Type 2 ORF2 Protein

[1]  Huizhi Guo,et al.  Immunization of mice by Hollow Mesoporous Silica Nanoparticles as carriers of Porcine Circovirus Type 2 ORF2 Protein , 2012, Virology Journal.

[2]  Linlin Li,et al.  Mesoporous Silica Nanoparticles: Synthesis, Biocompatibility and Drug Delivery , 2012, Advanced materials.

[3]  Yaping Li,et al.  Controlled intracellular release of doxorubicin in multidrug-resistant cancer cells by tuning the shell-pore sizes of mesoporous silica nanoparticles. , 2011, ACS nano.

[4]  M. Haessig,et al.  Vaccination of Dams Increases Antibody Titer and Improves Growth Parameters in Finisher Pigs Subclinically Infected with Porcine Circovirus Type 2 , 2011, Clinical and Vaccine Immunology.

[5]  Dehui Sun,et al.  Hollow mesoporous silica nanoparticles for intracellular delivery of fluorescent dye , 2011, Chemistry Central journal.

[6]  J. Segalés,et al.  Recent advances in the epidemiology, diagnosis and control of diseases caused by porcine circovirus type 2. , 2011, Veterinary journal.

[7]  K. Podgórska,et al.  Efficacy of different protocols of vaccination against porcine circovirus type 2 (PCV2) in a farm affected by postweaning multisystemic wasting syndrome (PMWS). , 2010, Comparative immunology, microbiology and infectious diseases.

[8]  Huizhi Guo,et al.  Development and validation of an ELISA using a protein encoded by ORF2 antigenic domain of porcine circovirus type 2 , 2010, Virology Journal.

[9]  Yu Chen,et al.  Core/shell structured hollow mesoporous nanocapsules: a potential platform for simultaneous cell imaging and anticancer drug delivery. , 2010, ACS nano.

[10]  T. Opriessnig,et al.  Comparison of the effectiveness of passive (dam) versus active (piglet) immunization against porcine circovirus type 2 (PCV2) and impact of passively derived PCV2 vaccine-induced immunity on vaccination. , 2010, Veterinary microbiology.

[11]  A. Mankertz,et al.  Porcine circoviruses--small but powerful. , 2009, Virus research.

[12]  Yong-Min Huh,et al.  Hollow silica nanocontainers as drug delivery vehicles. , 2008, Langmuir : the ACS journal of surfaces and colloids.

[13]  P. Jiang,et al.  Protection of pigs against post-weaning multisystemic wasting syndrome by a recombinant adenovirus expressing the capsid protein of porcine circovirus type 2. , 2007, Veterinary microbiology.

[14]  Hirokazu Miyoshi,et al.  Encapsulated ultrasound microbubbles: therapeutic application in drug/gene delivery. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[15]  J. Kwang,et al.  The ORF3 Protein of Porcine Circovirus Type 2 Is Involved in Viral Pathogenesis In Vivo , 2006, Journal of Virology.

[16]  Yufang Zhu,et al.  Stimuli-responsive controlled drug release from a hollow mesoporous silica sphere/polyelectrolyte multilayer core-shell structure. , 2005, Angewandte Chemie.

[17]  Jiyong Zhou,et al.  In vitro expression, monoclonal antibody and bioactivity for capsid protein of porcine circovirus type II without nuclear localization signal. , 2005, Journal of biotechnology.

[18]  A. C. Hunter,et al.  Nanomedicine: current status and future prospects , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[19]  P. Lekcharoensuk,et al.  Epitope Mapping of the Major Capsid Protein of Type 2 Porcine Circovirus (PCV2) by Using Chimeric PCV1 and PCV2 , 2004, Journal of Virology.

[20]  A. Bøtner,et al.  Immunisation against PCV2 structural protein by DNA vaccination of mice. , 2004, Vaccine.

[21]  E. Albina,et al.  Protection of swine against post-weaning multisystemic wasting syndrome (PMWS) by porcine circovirus type 2 (PCV2) proteins. , 2003, Vaccine.

[22]  M. Kiupel,et al.  Viral Replication and Lesions in BALB/c Mice Experimentally Inoculated with Porcine Circovirus Isolated from a Pig with Postweaning Multisystemic Wasting Disease , 2001, Veterinary pathology.

[23]  J. Ellis,et al.  Production, characterisation and applications of monoclonal antibodies to porcine circovirus 2 , 2001, Archives of Virology.

[24]  E. Albina,et al.  Identification of an immunorelevant ORF2 epitope from porcine circovirus type 2 as a serological marker for experimental and natural infection , 2001, Archives of Virology.

[25]  J. Hemmen,et al.  Cytokine-modulated regulation of helper T cell populations. , 2000, Journal of theoretical biology.

[26]  S. Sorden,et al.  Open reading frame 2 of porcine circovirus type 2 encodes a major capsid protein. , 2000, The Journal of general virology.

[27]  A. Hill,et al.  Vaccines against intracellular infections requiring cellular immunity , 2000, Nature.

[28]  E. Albina,et al.  Differential recognition of ORF2 protein from type 1 and type 2 porcine circoviruses and identification of immunorelevant epitopes. , 2000, The Journal of general virology.

[29]  P. Kalinski,et al.  T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal. , 1999, Immunology today.

[30]  Katarina Wolf,et al.  Identification of a protein essential for replication of porcine circovirus. , 1998, The Journal of general virology.

[31]  S. Constant,et al.  Induction of Th1 and Th2 CD4+ T cell responses: the alternative approaches. , 1997, Annual review of immunology.

[32]  Kenneth M. Murphy,et al.  Functional diversity of helper T lymphocytes , 1996, Nature.

[33]  P. Galan,et al.  Lymphocyte subpopulations in the thymus, lymph nodes and spleen of iron-deficient and rehabilitated mice. , 1991, The Journal of nutrition.

[34]  T. Mosmann,et al.  Functional diversity of T lymphocytes due to secretion of different cytokine patterns , 1991, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[35]  L. Wang,et al.  Virology Journal , 1966, Nature.